STOCK TITAN

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Evaxion Biotech (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-Immunology™ powered vaccines, has scheduled its full year 2024 financial results announcement and business update for April 1, 2025, before Nasdaq CM market opening.

The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST. The event will be free and open to the public, featuring a presentation of results followed by a Q&A session. Participants must register in advance to receive dial-in details and a unique PIN code. A recording of the webcast will be made available on Evaxion's website after the event.

Evaxion Biotech (NASDAQ: EVAX), un'azienda TechBio in fase clinica focalizzata su vaccini potenziati dall'AI-Immunology™, ha programmato l'annuncio dei risultati finanziari per l'intero anno 2024 e un aggiornamento aziendale per 1 aprile 2025, prima dell'apertura del mercato Nasdaq CM.

Il Management Esecutivo dell'azienda ospiterà una conferenza telefonica e un webcast lo stesso giorno alle 14:30 CET/08:30 EST. L'evento sarà gratuito e aperto al pubblico, con una presentazione dei risultati seguita da una sessione di domande e risposte. I partecipanti devono registrarsi in anticipo per ricevere i dettagli per la chiamata e un codice PIN unico. Una registrazione del webcast sarà disponibile sul sito web di Evaxion dopo l'evento.

Evaxion Biotech (NASDAQ: EVAX), una empresa de TechBio en etapa clínica centrada en vacunas impulsadas por AI-Immunology™, ha programado el anuncio de sus resultados financieros del año completo 2024 y una actualización empresarial para el 1 de abril de 2025, antes de la apertura del mercado Nasdaq CM.

La Dirección Ejecutiva de la empresa llevará a cabo una conferencia telefónica y un webcast el mismo día a las 14:30 CET/08:30 EST. El evento será gratuito y abierto al público, con una presentación de resultados seguida de una sesión de preguntas y respuestas. Los participantes deben registrarse con antelación para recibir los detalles de acceso y un código PIN único. Una grabación del webcast estará disponible en el sitio web de Evaxion tras el evento.

Evaxion Biotech (NASDAQ: EVAX)는 AI-Immunology™ 기반의 백신에 중점을 둔 임상 단계의 TechBio 회사로, 2025년 4월 1일에 2024년 전체 연도 재무 결과 발표 및 사업 업데이트를 예정하고 있습니다. 이는 Nasdaq CM 시장 개장 전에 이루어질 것입니다.

회사의 경영진은 같은 날 14:30 CET/08:30 EST에 전화 회의 및 웹캐스트를 주최할 것입니다. 이 행사는 무료로 공개되며, 결과 발표 후 질의응답 세션이 포함됩니다. 참가자는 사전에 등록하여 전화 접속 세부정보 및 고유 PIN 코드를 받아야 합니다. 이벤트 후 Evaxion 웹사이트에서 웹캐스트 녹화본이 제공될 예정입니다.

Evaxion Biotech (NASDAQ: EVAX), une entreprise de TechBio en phase clinique axée sur les vaccins alimentés par AI-Immunology™, a prévu l'annonce de ses résultats financiers pour l'année complète 2024 et une mise à jour commerciale pour le 1er avril 2025, avant l'ouverture du marché Nasdaq CM.

La direction exécutive de l'entreprise animera une conférence téléphonique et un webinaire le même jour à 14h30 CET/08h30 EST. L'événement sera gratuit et ouvert au public, avec une présentation des résultats suivie d'une session de questions-réponses. Les participants doivent s'inscrire à l'avance pour recevoir les détails de connexion et un code PIN unique. Un enregistrement du webinaire sera disponible sur le site web d'Evaxion après l'événement.

Evaxion Biotech (NASDAQ: EVAX), ein klinisch tätiges TechBio-Unternehmen, das sich auf von AI-Immunologie™ unterstützte Impfstoffe konzentriert, hat die Bekanntgabe seiner Finanz Ergebnisse für das Gesamtjahr 2024 und ein Unternehmensupdate für den 1. April 2025 vor der Eröffnung des Nasdaq CM-Marktes geplant.

Das Management des Unternehmens wird am selben Tag um 14:30 CET/08:30 EST eine Telefonkonferenz und einen Webcast veranstalten. Die Veranstaltung ist kostenlos und für die Öffentlichkeit zugänglich, mit einer Präsentation der Ergebnisse, gefolgt von einer Frage- und Antwortsitzung. Die Teilnehmer müssen sich im Voraus registrieren, um Zugangsdaten und einen einzigartigen PIN-Code zu erhalten. Eine Aufzeichnung des Webcasts wird nach der Veranstaltung auf der Website von Evaxion verfügbar sein.

Positive
  • None.
Negative
  • None.

COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.

Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.

To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.

To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.

Contact information 
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96

mak@evaxion.ai 

About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 


FAQ

When will Evaxion Biotech (EVAX) release its 2024 annual financial results?

Evaxion Biotech will release its full year 2024 financial results on April 1, 2025, before the Nasdaq CM market opens.

How can investors join Evaxion's (EVAX) 2024 annual results conference call?

Investors must register in advance to receive dial-in numbers and a PIN code. The call begins at 14:30 CET/08:30 EST on April 1, 2025.

Will Evaxion's (EVAX) 2024 annual results presentation be available for replay?

Yes, a recording of the webcast will be available on Evaxion's website shortly after the event.

What topics will be covered in Evaxion's (EVAX) April 1, 2025 presentation?

The presentation will cover Evaxion's full year 2024 financial results and a business update, followed by a Q&A session.
Evaxion Biotech A/S

NASDAQ:EVAX

EVAX Rankings

EVAX Latest News

EVAX Stock Data

10.67M
5.97M
5.61%
0.86%
1.38%
Biotechnology
Healthcare
Link
Denmark
Horsholm